Titan Biotech (Transfer From Delhi To Raj.) Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 8.26 Cr
as on 10-12-2024
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 32.84 Cr
as on 10-12-2024
- Satisfied Charges ₹ 5.40 Cr
as on 10-12-2024
- Revenue 1.11%
(FY 2022)
- Profit -24.64%
(FY 2022)
- Ebitda -25.41%
(FY 2022)
- Net Worth 31.03%
(FY 2022)
- Total Assets 24.83%
(FY 2022)
About Titan Biotech (Transfer From Delhi To Raj.)
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524717.
The Corporate was formerly known as Titan Medicares Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 8.26 Cr.
The company currently has active open charges totaling ₹32.84 Cr. The company has closed loans amounting to ₹5.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Titan Biotech Ltd. (Transfer From Delhi To Raj.) India are Prem Gupta as CFO and Charanjit Singh as Company Secretary. Naresh Singla, Suresh Singla, Manju Singla, and Eight other members serve as directors at the Company.
- CIN/LLPIN
L74999RJ1992PLC013387
- Company No.
013387
- Stock Symbol
BSE : 524717
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Feb 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Alwar, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Titan Biotech Ltd. (Transfer From Delhi To Raj.) offer?
Titan Biotech Ltd. (Transfer From Delhi To Raj.) offers a wide range of products and services, including Flavours & Aromatics, Food Emulsifiers, Food Additive, Inorganic Salts, Sodium Selenite, Dough Conditioners, Chemical Reagents & Catalysts, Bio Chemicals, Ayurvedic & Herbal Extracts, Anti Bacterial & Fungal Extracts.
Who are the key members and board of directors at Titan Biotech (Transfer From Delhi To Raj.)?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Singla  | Managing Director | 01-May-2002 | Current |
| Suresh Singla | Managing Director | 01-Oct-2012 | Current |
| Prem Gupta | CFO | 01-May-2014 | Current |
| Charanjit Singh | Company Secretary | 21-Apr-2021 | Current |
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Supriya Singla | Director | 01-Oct-2012 | Current |
| Rohit Jain | Director | 26-Jul-2021 | Current |
| Raja Singla | Whole-Time Director | 01-Oct-2022 | Current |
| Manju Singla | Director | 23-Jun-2001 | Current |
| Udit Singla | Whole-Time Director | 01-Oct-2023 | Current |
| Dhairya Madan | Director | 01-Oct-2023 | Current |
Financial Performance and Corporate Structure Insights of Titan Biotech (Transfer From Delhi To Raj.).
Titan Biotech Ltd. (Transfer From Delhi To Raj.), for the financial year ended 2022, experienced modest growth in revenue, with a 1.11% increase. The company also saw a substantial fall in profitability, with a 24.64% decrease in profit. The company's net worth Soared by an impressive increase of 31.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Titan Biotech (Transfer From Delhi To Raj.)?
In 2022, Titan Biotech (Transfer From Delhi To Raj.) had a promoter holding of 55.87% and a public holding of 44.13%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Titan Securities LimitedActive 31 years 10 monthsNaresh Singla, Suresh Singla and 1 more are mutual person
Stalwart Nutritions Private LimitedActive 6 years 8 daysRaja Singla, Udit Singla and 1 more are mutual person
Peptech Biosciences LimitedActive 13 years 1 monthNaresh Singla, Suresh Singla and 4 more are mutual person
Emprise Productions Private LimitedActive 8 years 4 monthsRaja Singla and Shivom Singla are mutual person
Titan Agritech LimitedActive 1 year 11 monthsNaresh Singla, Raja Singla and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 12 Aug 2024 | ₹1.20 M | Open |
Hdfc Bank Limited Creation Date: 08 Sep 2022 | ₹6.56 Cr | Open |
Hdfc Bank Limited Creation Date: 21 Jul 2022 | ₹4.50 M | Open |
How Many Employees Work at Titan Biotech (Transfer From Delhi To Raj.)?
Titan Biotech (Transfer From Delhi To Raj.) has a workforce of 377 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Titan Biotech (Transfer From Delhi To Raj.), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Titan Biotech (Transfer From Delhi To Raj.)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
